Time Toxicity Experienced by Early-Phase Cancer Clinical Trial Participants.
Sienna M DurbinDebra M LundquistAndrea PelletierRachel B JimenezLaura A PetrilloJanice S KimKaitlyn LynchMegan HealyAndrew E JohnsonNicholas OllilaVaishnavi YalalaBenjamin MalowitzAllison M KehlmannNicholas ChevalierVictoria TurbiniViola BameHope HeldrethJenipher SilvaCasandra McIntyreDejan JuricRyan David NippPublished in: JCO oncology practice (2024)
In this cohort of EP-CT participants, patients spent more than one-fifth of days on trial with health care contact. We identified characteristics associated with higher time toxicity and found that high toxicity correlated with worse clinical outcomes. These data could help inform patient-clinician discussions about EP-CTs, guide future trial design, and identify at-risk patients.
Keyphrases
- clinical trial
- healthcare
- end stage renal disease
- newly diagnosed
- ejection fraction
- study protocol
- phase ii
- prognostic factors
- phase iii
- computed tomography
- randomized controlled trial
- patient reported outcomes
- artificial intelligence
- electronic health record
- deep learning
- young adults
- papillary thyroid
- data analysis
- lymph node metastasis
- squamous cell
- pet ct